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http://www.diagnosticpathology.org/content/8/1/204RESEARCH Open AccessHuman papillomavirus genotypes in human
immunodeficiency virus-positive patients with
anal pathology in Madrid, Spain
Benjamín García-Espinosa1, Ernesto Moro-Rodríguez1,3* and Emilio Álvarez-Fernández2Abstract
Background: We studied anal specimens to determine the distribution of human papillomavirus (HPV) genotypes
and co-infection occurrence. This information will contribute to the knowledge of HPV genotype distributions and
provide an estimate of the prevalence of different oncogenic HPV genotypes found in patients in Madrid (Spain).
Methods: We studied a total of 82 anal biopsies from the Hospital General Universitario Gregorio Marañón of
Madrid. These included 4 specimens with benign lesions, 52 specimens with low-grade anal squamous intraepithelial
lesion, 24 specimens with high-grade anal squamous intraepithelial lesions and 2 specimens with invasive anal
carcinoma. HPV genotyping was performed with PCR amplification and reverse dot blot hybridization.
Results: We detected 33 different HPV genotypes, including 16 HPVs associated with a high risk of carcinogenesis, 3
HPVs associated with a highly likely risk of carcinogenesis and 14 HPVs associated with a low-risk of carcinogenesis. In
two specimens, an uncharacterized HPV genotype was detected. The most frequent HPV genotypes found were
HPV-16 (10.3%; 95% CI: 6.6%-15.1%), HPV-52 (8.5%; 95% CI: 5.2%-13%) and HPV-43/44 (7.6%; 95% CI: 4.5%-11.9%).
HPV-18 was only detected in 0.9% (95% CI: 0.1%-3.2%) of the total viruses detected in all lesions. HPV co-infections
were found in 83.9% of all types of lesions. The majority of cases (90.2%) were concomitantly infected with the human
immunodeficiency virus (HIV).
Conclusion: The prevalence of high-risk carcinogenic genotypes in anal pathological samples was remarkable. Therefore,
further studies that include a greater number of samples, particularly invasive carcinoma cases are needed to evaluate
the potential influence of these HPV genotypes in the appearance of anal carcinomas. Also, the influence of other
accompanying infections should be evaluated clarify the appearance of this type of carcinoma.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
2075238024106058.
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Anal squamous cell carcinoma is an uncommon tumour.
However, it is the most common type of cancer malig-
nancy that arises from the anal margin. Less frequent
anal malignancies include neoplasms from the anal
canal, which have been poorly differentiated and are* Correspondence: jemoro@uninet.edu
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distribution, and reproduction in any mediumtypically non-keratinizing, and malignancies that arise
around the dentate line which have been defined as tran-
sitional carcinomas [1,2].
In Spain, anal carcinoma is estimated to represent
1.8% of all tumours of the digestive tract. However, in
the last 25 years, its incidence has increased in Spain, as
in other Western countries. This increased frequency has
been attributed to different factors, including increases
in human papillomavirus (HPV) infections and other
sexually-transmitted infections, the pandemic of human
immunodeficiency virus (HIV) and the increasinglyCentral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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and heterosexual settings [3-6].
HPV is the most common sexually-transmitted infec-
tion world-wide. Different lesions range from simple
warts or condyloma acuminatum to severe changes like
epithelial dysplasia and invasive carcinoma. The presen-
tation varies with the different specific HPV genotypes
that can infect the anogenital or oral mucous membrane.
Of 100 recognized HPV subtypes, over 80 have a com-
pletely sequenced genome to date; 35 are specific for
the cervical and anal epithelium. Each subtype carries
a variable capacity for causing dysplastic changes. A
recent systematic review showed that 72% of anal in-
vasive carcinomas were associated with the oncogenic
subtypes, HPV-16 and HPV-18. Currently, the relation-
ships between the different HPV subtypes and their cor-
responding effects on the anogenital epithelium are well
known [7,8].
Patients in immunosuppressed conditions are at in-
creased risk for developing multiple HPV-related benign
and malignant anogenital tumours. Patients that are
HIV-positive fail to clear HPV-related diseases because
they have insufficient cell-mediated immunity to control
latent HPV infections. As HIV/AIDS is increasingly man-
aged as a chronic disease, greater attention should be
focused on cancer screening and prevention, particularly
for non-AIDS-defining cancers in the anus and liver, and
for Hodgkin lymphoma, which appears to have increased
incidence [9]. A recent meta-analysis estimated that the
anal cancer incidence was much higher in men that were
HIV-positive (46 per 100,000 per year) than in those that
were HIV-negative (5 per 100,000 per year) [10]. At the
same time, patients that receive organ transplants and fol-
low chronic immunosuppressive treatments are at risk for
anal cancer [11].
Premalignant changes have been classified as low-
grade and high-grade anal squamous intraepithelial
lesions (LASIL and HASIL, respectively), based on
criteria for evaluating similar lesions in the cervix;
however, the classifications, follow the lower anogeni-
tal squamous terminology (LAST). This two-tiered
scale defines low-grade lesions as those generally related
to self-limiting HPV infections and the high-grade lesions
as those with potential for progression to invasive carcin-
oma (IC) [12,13]. ASILs are most frequently found in
the anal canal and perianal skin, and multicentricity is
common [14].
To date, no study has investigated the relationship be-
tween HPV and ASILs in Spain; furthermore the preva-
lence of HPV is largely unknown. In other European
countries, few studies have been published that estimated
the HPV genotype distribution in anal lesions, in popula-
tions that were either HIV-negative and HIV-positive; thus,
further studies in this field are needed [15-20].The present study aimed to determine the HPV geno-
type distribution and co-infection rate in anal specimens
from individuals in Madrid (Spain). The findings pre-
sented in this paper will contribute to the knowledge of
HPV genotype distribution and provide an estimate of
the prevalence of oncogenic HPV types in anal lesions
among Spanish patients.
Materials and methods
Specimen collection and diagnosis
This study had a cross-sectional and retrospective de-
sign. We obtained samples from 226 individuals with
anal lesions diagnosed in the Hospital General Universi-
tario “Gregorio Marañón” of Madrid, between February
2012 and March 2013. The hospital provided healthcare
to a population of about 750,000 individuals (11.5% of
the population of the regional community of Madrid).
All patients were enrolled in a screening program intro-
duced in the hospital to detect early sings of anal carcin-
oma. These patients were routinely subjected to anal
examinations, followed by cytology. Suspected cases under-
went a proctoscopy and were examined under anaesthesia.
Suspicious lesions, identified by acetic acid staining, were
mapped and biopsied for histological confirmation, accord-
ing to the recommendations of the European Society for
Medical Oncology Clinical Practical Guidelines [21].
The present study includes samples of anal lesions
(specimens of fixed tissue sections from biopsies)
collected from different departments of the Hospital
General Universitario “Gregorio Marañón” of Madrid
and submitted to the anatomical pathology laboratory
for study.
The study included 82 samples from patients with an
anatomic-pathological diagnosis of anal HPV-related le-
sions. Of these 82 patients, 74 with HIV infections were
selected to investigate the presence of HPV in corre-
sponding anal lesions. In 6 of these cases, the presence
of HPV was negative, and in 6 other cases, the anal speci-
mens were inadequate for HPV testing; in 62 HIV-positive
cases, HPV was detected in anal lesions (HIV&HPV). The
latter 62 cases were studied further. The average age of
these patients was 45.7 years, and the majority (n = 58;
93.5%) was male.
The HIV&HPV samples included 1 benign lesion
(condyloma acuminatum), 40 LASILs (including flat
condyloma, mild dysplasia and ASIL 1), 20 HASILs
(including moderate dysplasia, ASIL 2, severe dysplasia,
ASIL 3, and carcinoma in situ) and 1 IC.
Informed consent was not required for this study be-
cause the results were based on routine HPV genotyp-
ing, and the analyses were performed as an adjunct to
the cytological and histological study, in an anatomic
pathology laboratory. The detection and genotyping was
performed in a clinical setting, and patient confidentiality











BL 1 (1.6) 1 (1.6) 0 (0)
LASIL 40 (64.5) 8 (12.9) 32 (51.6)
HASIL 20 (32.3) 1 (1.6) 19 (30.6)
IC 1 (1.6) 0 (0) 1 (1.6)
Total specimens 62 (100) 10 (16.1) 52 (83.9)
* Number of cases and percentages referred to the total of specimens (62).
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the patients; thus it was not possible to determine the
ethnicity of each patient. The study was supervised by
the Ethics committee of the hospital (Comité ético de
investigación clínica).
Detection and genotyping of HPV
DNA for each case was extracted from an anal, liquid-
based, cytology sample. The isolated DNA was used as a
template for PCR amplification to detect the presence of
HPV DNA. We used primers specific for the GP5-6 L1
consensus region. PCR amplification was targeted to a
fragment of 450 bp in the L1 consensus region. We per-
formed reverse dot blot hybridization with probes specific
for each genotype (based on “flow-through” technology).
The amplification products were separated with agarose
gel electrophoresis and stained with ethidium bromide,
which allowed detection of the products with a UV transil-
luminator. A sample was considered positive when a band
of 150 bp was detected (GenoFlow HPV Array Test Kit ©
Diagcor Bioscience Incorporation Limited, Hong Kong).
This diagnostic kit was intended for simultaneous
screening and genotyping of 33 HPV types. These HPV
types included 15 associated with a high-risk of carcino-
genesis (HR; HPV-16, HPV-18, HPV-31, HPV-33, HPV-
35, HPV-39, HPV-45, HPV-51, HPV-52, HPV-56, HPV-58,
HPV-59, HPV-68, HPV-73 and HPV-82), 3 associated with
a highly-probable-risk of carcinogenesis (PHR; HPV-26,
HPV-53, HPV-66) and 15 associated with a low-risk of car-
cinogenesis (LR; HPV-6, HPV-11, HPV-40, HPV-42, HPV-
43, HPV-44, HPV-54, HPV-55, HPV-57, HPV-61, HPV-70,
HPV-71, HPV-72, HPV-81 and HPV-84).
This kit was not able to detect some genotypes separ-
ately; thus, some were detected as couples (HPV-40/61,
HPV-43/44, HPV-54/55, HPV-57/71, HPV-66/68 and
HPV-84/26).
Two methods were used to estimate the frequency of
HPV positivity. First, the percentage of lesions infected
by one or several genotypes; and second, the percentage
of a given HPV in the total number of viruses detected
in all lesions and each group of lesions.
Statistical analysis
Statistical analysis was performed with Stata version
11.1/SE (StataCorp. LP, TX, USA). Relative frequencies
of HPV genotypes were estimated as percentages with
95% confidence intervals (95% CI) assessed with Clopper-
Pearson method and based on the exact binomial distribu-
tion of the tail areas.
Results
Distribution of viral genotypes
At least 83.8% of the entire group of HIV-positive speci-
mens studied was also HPV-positive (HIV&HPV; 62/74).Concomitant infections were found in a large proportion
of HIV&HPV samples. The most frequent concomitant
infections were from Treponema pallidum (40.3%) and
Hepatitis B and/or C virus (30.6%).
As shown in Table 1, among the total group of speci-
mens, the most frequent lesion was LASIL (64.5%),
followed by HASIL (32.3%). Only one IC was diagnosed
(1.6%). HPV co-infection were found in 52 of 62 cases
(83.9%).
Based on all the data, we detected 33 different HPV
genotypes, including 16 HR-HPVs, 3 PHR-HPVs and 14
LR-HPVs. As shown in Table 2, among all the viruses,
HPV-16 was detected most frequently (10.3%; 95% CI:
6.6%-15.1%). This was followed by, in order of decreas-
ing frequency, HPV-52 (8.5%; 95% CI: 5.2%-13%), HPV-
43/44 (7.6%; 95% CI: 4.5%-11.9%), HPV-6 (6.7%; 95% CI:
3.8%-10.8%) and HPV-51 (6.3%; 95% CI: 3.5%-10.3%).
HPV-18 was only detected in 2 lesions (0.9%; 95% CI:
0.1%-3.2%) among HIV&HPV positive samples.
In the majority of lesions, at least one HR-HPV was
detected. Among all the lesions, HPV-16 was present in
37.1% (95% CI: 25.2%-50.3%), HPV-52 in 30.6% (95% CI:
19.6%-43.7%), HPV-51 in 22.6% (95% CI: 12.9%-35%),
HPV-31 in 21% (95% CI: 11.7%-33.2%), and HPV-58 in
21.0% (95% CI: 11.7%-33.2%). Two cases (0.9%) were
classified as an uncharacterized HPV type (HPV-X, 95%
CI: 0.1%-3.2%), but we suspect that this classification
was most likely related to the missed detection of known
HPV types; i.e., it was probably not associated with an
undiscovered HPV type (Table 2).
Relationship between diagnoses and HPV genotypes
Among the LASIL samples, HPV-16 was not the most
common genotype. The most frequent type was HPV-52
(9.2%; 95% CI: 5%-15.3%); this was followed by, in order
of decreasing frequency, HPV-16 (8.5%; 95% CI: 4.5%-
14.4%), HPV-43/44 (7.8%; 95% CI: 4%-13.5%), HPV-51
(7.1%; 95% CI: 3.5%-12.7%) and HPV-11 (6.4%; 95% CI:
3%-11.8%). HPV-18 was not detected in this group.
Among the LASILs, HR-HPVs were detected more fre-
quently than LR-HPVs (approximately 58.2% vs. 36.9%)
Table 2 Distribution of HPV genotypes found in the study according to the pathological diagnosis
Genotype found Total lesions LASIL HASIL
N % * CI95% % ** CI95% N % * CI95% % ** CI95% N % * CI95% % ** CI95%
HR-HPVs
16 23 10.3 6.6-15.1 37.1 25.2-50.3 12 8.5 4.5-14.4 30.0 16.6-46.5 10 12.7 6.2-22.0 50.0 27.2-72.8
18 2 0.9 0.1-3.2 3.2 0.4-11.2 0 0.0 0.0-2.6 0.0 0.0-8.8 2 2.5 0.3-8.8 10.0 1.2-31.7
31 13 5.8 3.1-9.8 21.0 11.7-33.2 7 5.0 2.0-10.0 17.5 7.3-32.8 6 7.6 2.8-15.8 30.0 11.9-54.3
33 6 2.7 1.0-5.8 9.7 3.6-19.9 2 1.4 0.2-5.0 5.0 0.6-16.9 4 5.1 1.4-12.5 20.0 5.7-43.7
35 5 2.2 0.7-5.2 8.1 2.7-17.8 3 2.1 0.4-6.1 7.5 1.6-20.4 2 2.5 0.3-8.8 10.0 1.2-31.7
39 5 2.2 0.7-5.2 8.1 2.7-17.8 4 2.8 0.8-7.1 10.0 2.8-23.7 1 1.3 0.0-6.9 5.0 0.1-24.9
45 8 3.6 1.6-6.9 12.9 5.7-23.9 6 4.3 1.6-9.0 15.0 5.7-29.8 2 2.5 0.3-8.8 10.0 1.2-31.7
51 14 6.3 3.5-10.3 22.6 12.9-35.0 10 7.1 3.5-12.7 25.0 12.7-41.2 4 5.1 1.4-12.5 20.0 5.7-43.7
52 19 8.5 5.2-13.0 30.6 19.6-43.7 13 9.2 5.0-15.3 32.5 18.6-49.1 6 7.6 2.8-15.8 30.0 11.9-54.3
56 5 2.2 0.7-5.1 8.1 2.7-17.8 4 2.8 0.8-7.1 10.0 2.8-23.7 1 1.3 0.0-6.9 5.0 0.1-24.9
58 13 5.8 3.1-9.8 21.0 11.7-33.2 6 4.3 1.6-9.0 15.0 5.7-29.8 7 8.9 3.6-17.4 35.0 15.4-59.2
59 7 3.1 1.3-6.4 11.3 4.7-21.9 3 2.1 0.4-6.1 7.5 1.6-20.4 4 5.1 1.4-12.5 20.0 5.7-43.7
73 5 2.2 0.7-5.1 8.1 2.7-17.8 4 2.8 0.8-7.1 10.0 2.8-23.7 1 1.3 0.0-6.9 5.0 0.1-24.9
81 5 2.2 0.7-5.1 8.1 2.7-17.8 3 2.1 0.4-6.1 7.5 1.6-20.4 1 1.3 0.0-6.9 5.0 0.1-24.9
82 1 0.4 0.0-2.5 1.6 0.0-8.7 0 0.0 0.0-2.6 0.0 0.0-8.8 1 1.3 0.0-6.9 5.0 0.1-24.9
PHR/HR-HPVs
66/68 6 2.7 1.0-5.8 9.7 3.6-19.9 5 3.5 1.2-8.1 12.5 4.2-26.8 1 1.3 0.0-6.9 5.0 0.1-24.9
PHR-HPVs
53 6 2.7 1.0-5.8 9.7 3.6-19.9 4 2.8 0.8-7.1 10.0 2.8-23.7 2 2.5 0.3-8.8 10.0 1.2-31.7
LR/PHR-HPVs
84/26 2 0.9 0.1-3.2 3.2 0.4-11.2 1 0.7 0.0-3.9 2.5 0.1-13.2 1 1.3 0.0-6.9 5.0 0.1-24.9
LR-HPVs
6 15 6.7 3.8-10.8 24.2 14.2-36.7 8 5.7 2.5-10.9 20.0 9.1-35.6 6 7.6 2.8-15.8 30.0 11.9-54.3
11 12 5.4 2.8-9.2 19.4 10.4-31.4 9 6.4 3.0-11.8 22.5 10.8-38.5 3 3.8 0.8-10.7 15.0 3.2-37.9
42 5 2.2 0.7-5.1 8.1 2.7-17.8 3 2.1 0.4-6.1 7.5 1.6-20.4 2 2.5 0.3-8.8 10.0 1.2-31.7
70 7 3.1 1.3-6.4 11.3 4.7-21.9 5 3.5 1.2-8.1 12.5 4.2-26.8 2 2.5 0.3-8.8 10.0 1.2-31.7
72 6 2.7 1.0-5.8 9.7 3.6-19.9 4 2.8 0.8-7.1 10.0 2.8-23.7 2 2.5 0.3-8.8 10.0 1.2-31.7
40/61 8 3.6 1.6-6.9 12.9 5.7-23.9 7 5.0 2.0-10.0 17.5 7.3-32.8 1 1.3 0.0-6.9 5.0 0.1-24.9
43/44 17 7.6 4.5-11.9 27.4 16.9-40.2 11 7.8 4.0-13.5 27.5 14.6-43.9 6 7.6 2.8-15.8 30.0 11.9-54.3
54/55 5 2.2 0.7-5.1 8.1 2.7-17.8 4 2.8 0.8-7.1 10.0 2.8-23.7 1 1.3 0.0-6.9 5.0 0.1-24.9
57/71 1 0.4 0.0-2.5 1.6 0.0-8.7 1 0.7 0.0-3.9 2.5 0.1-13.2 0 0.0 0.0-4.6 0.0 0.0-16.8
X 2 0.9 0.1-3.2 3.2 0.4-11.2 2 1.4 0.2-5.0 5.0 0.6-16.9 0 0.0 0.0-4.6 0.0 0.0-16.8
N: total number of times, which each genotype, was detected.
* Percentages referred to the total number of virus detected (223 viruses in the Total of lesions, 141 in the LASIL and 79 in HASIL).
** Percentages referred to the number of lesions infected by one or several genotypes (62 Total lesions, 40 LASIL and 20 HASIL).
CI95%: 95% confidence intervals used for estimate percentages.
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tions (approximately 12.5%).
However, among the HASIL samples, HPV-16 was the
most common genotype (12.7%; 95% CI: 6.2%-22%),
followed by HPV-58 (8.9%; 95% CI: 3.6%-17.4%) and the
group of HPV-31, HPV-52, HPV-6 and HPV-43/44
(7.6%; 95% CI: 2.8%-15.8%). HPV-18 was only detected
in 2.5% (95% CI: 0.3%-8.8%). Also among the HASILs,HR-HPVs were detected more frequently than LR-
HPVs (approximately 67.1% vs. 29.1%) a greater pro-
portion of HR-HPVs were found in HASIL than in
LASIL samples.
The only case of IC was found in a 67 year old male
with a long history of Candidiasis and Cystoporidium in-
fections. The sample from this individual also exhibited
a double infection with HPV-16 and HPV-81.
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between pathology groups vs. HPV risk types is shown
in Table 2.
Figure 1 shows a chart of the distribution of all cases
according to patient age and the frequency of each
lesion.
Genotypes in co-infections
The percentages of multiple infections were very high: 80%
in LASIL cases, 95% in HASIL cases, and 100% in IC cases.
Multiple infections were not detected in benign lesions.
As shown in Table 3, among all the lesions with mul-
tiple HPV infections, the most common included four
different genotypes (25.0%); similar frequencies were
found for double genotype infections (21.2%) and triple
genotype infections (19.2%). Five different genotypes
were found in 17.3% of cases, and six genotypes were
found in 13.5% of cases. More than six different geno-
types were found in only two cases (3.8%). These results
indicated a high prevalence of HPV co-infections.
Among the LASIL cases with multiple HPV infections,
HPV-16 was the most common type found (9.0%; CI:
4.7%-15-2) followed by HPV-43/44, HPV-51 and HPV-52Figure 1 Chart showing the distribution of all cases according to thei(7.5%; CI: 3.7%-13.4%). HPV-11 occurred in 6.8% (CI:
3.1%-12.5%). Among the HASIL cases with multiple infec-
tions, the HPV genotype distribution was similar to that
found in all the entire group of HASIL cases.
HPV co-infection distributions are shown in Table 4.
Discussion
This study included individuals with visible, HPV-related le-
sions in the anogenital area, assessed by careful inspection
of the external genitalia and perianal area. Also, an intra-
anal examination was performed with a digital rectal exam
and high-resolution, flexible anoscopy, prior to an acetic
acid stain of the mucosa. The population included was
nearly universally HIV-infected; they were identified in an
anal screening program conducted to prevent anal cancer.
In all the cases included in this study, a HPV genotyping
assay was routinely performed on cytologic specimens.
Some authors hold that the analysis of anal cytology for
HPV may lead to an overestimation of genotype-specific
associations with dysplasia [22]; however, given the multi-
focal characteristics of these lesions, we chose this proced-
ure, because of it provided the ability to sample the entire
anal canal and surface.r age and the frequency of each lesion.
Table 3 Pathological diagnoses and co-infection occurrence
N (%)
Pathological diagnosis 2 HPV types 3 HPV types 4 HPV types 5 HPV types 6 HPV types >6 HPV types Total
LASIL 8 (15.4) 7 (13.5) 5 (9.6) 5 (9.6) 5 (9.6) 2 (3.8) 32 (61.5)
HASIL 2 (3.8) 3 (5.8) 8 (15.4) 4 (7.7) 2 (3.8) 0 (0.0) 19 (36.5)
IC 1 (1.9) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.9)
Total 11 (21.2) 10 (19.2) 13 (25.0) 9 (17.3) 7 (13.5) 2 (3.8) 52 (100.0)
N: total of times, which each number, of genotypes was detected.
Percentage referred to total of co-infections (52).
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publically available that estimated the type-specific
prevalence of HPV in preinvasive anal lesions among pa-
tients that were HIV-seropositive in Spain. Among the
results from this study, the main finding was the unex-
pectedly high presence of high-risk HPV genotypes in
patients that were HIV-seropositive with anus pathology.
The most frequent genotype found in all lesions was
HPV-16 followed (in descending order) by HPV-52,
HPV-43/44, HPV-6, HPV-51, HPV-31 and HPV-58. Four
of these seven viruses belong to the species, group 9, of
the genus, Alpha-papillomavirus, and five are known to
be high-risk, oncogenic viruses [23,24]. This finding is
important because it suggested that the anal lesions in
this population might have had a greater predisposition
to progression than initially expected. Furthermore,
among those genotypes, we highlighted HPV-16, HPV-
58, and HPV-31 because they showed an increased fre-
quency in HASILs compared to LASILs.
The above suspicion was also noted by Machalek et al.
in a recent meta-analysis. They calculated a theoretical
rate of progression from HASIL to anal cancer of about
one in 600 per year in men that had sex with another
man (MSM) and were HIV-positive, in contrast, the rate
was only one in 4000 per year in MSM that were HIV-
negative [10]. Similarly, this risk for anal cancer has been
described as twice as high among MSM with HIV-
infections that among those without HIV-infections [3].
In this context, it is currently well known that individ-
uals that are HIV-seropositive have an increased rate of
anal epithelial pathology related to HPV infections com-
pared to individuals that are HIV-seronegative [25-27].
In the series presented here, men outnumbered women
by 15:1, with an average age of 46 years. All individuals
were HIV-infected, and they were under treatment with
highly active antiretroviral therapy (HAART). Among
this cohort, it was relatively common to find concomi-
tant infections, like syphilis and hepatitis B and/or C.
This profile of patients was not surprising because for
years, works by Daling 1982, Peters 1984, Croxson 1984,
and Frazer 1986 have described the striking frequency of
syphilis, anal warts, and ASIL in homosexual men, with
or without AIDS [28-31].Of note, it may be important that in our series of pa-
tients mostly belonged to a population born between
1958 and 1992. This age group may be related to the
probability of survival with AIDS and the possible loss of
HIV-infected patients in previous years; thus, relatively
younger men were more highly represented compared to
those born between 1938 and 1957. This fact can be ex-
plained by the undoubted benefit of HAART, which was
introduced in 1996.
The results of this paper were consistent with those re-
ported recently, which found the most frequent genotype
was the HPV-16, and that HIV-seropositive patients exhib-
ited the highest proportion of multiple HPV co-infections
[7,15,19,22,32]. However, we note that there were some
differences between the HPV genotypes found in our
study and those found in other populations. These differ-
ences may be explained by geographical diversity. For
example, in the French EdiTH V study the most fre-
quent HPV genotypes found among HIV-seropositive
cases were HPV-16 (59.6%), HPV-18 (15.4%), HPV-68
(13.4%), and HPV-51 and HPV-52 (11.5%) [20]. Similarly,
a few years earlier, Orlando et al. reported in Italy that
the genotypes identified most frequently were HPV-16
(21.69%), HPV-6 (18.16%), HPV-11 (16.27%), HPV-58
(5.19%), HPV-30 (4.72%), HPV-26 (4.24%) and HPV-18
(3.07%) [19].
The frequency of cases with the HPV-18 genotype in
our study was not as high as that published in other
international series [32,33]. We had found a similar dis-
crepancy in previous work on intraepithelial neoplasm
and invasive carcinomas of the cervix. However, this
lower frequency of HPV-18 was consistent with other
studies conducted in Spain where the HPV-18 type did
not appear to be as common in the general population
as it was in other countries [34,35].
As stated above, the patients with HIV-infections were
more likely to have multiple infections and more fre-
quently had oncogenic HPV types than those without
HIV-infections. In our series, 83.9% of lesions had mul-
tiple infections, which was a higher rate than those re-
ported by Palesfsky and Hesson [26,27]. Hesson et al. also
found that multiple HPV infections occurred more fre-
quently among patients with low levels of lymphocytes
Table 4 HPV genotype distribution in coinfection cases
Genotype found LASIL HASIL
N % * CI95% % ** CI95% N % * CI95% % ** CI95%
HR-HPVs
16 12 9.0 4.7-15.2 37.5 21.1-56.3 10 12.8 6.3-22.3 52.6 28.9-75.6
18 0 0.0 0.0-2.7 0.0 0.0-10.9 2 2.6 0.3-9.0 10.5 1.3-33.1
31 6 4.5 1.7-9.6 18.8 7.2-36.4 6 7.7 2.9-16.0 31.6 12.6-56.6
33 2 1.5 0.2-5.3 6.3 0.8-20.8 4 5.1 1.4-12.6 21.1 6.1-45.6
35 3 2.3 0.5-6.5 9.4 2.0-25.0 2 2.6 0.3-9.0 10.5 1.3-33.1
39 3 2.3 0.5-6.5 9.4 2.0-25.0 1 1.3 0.0-6.9 5.3 0.1-26.0
45 6 4.5 1.7-9.6 18.8 7.2-36.4 2 2.6 0.3-9.0 10.5 1.3-33.1
51 10 7.5 3.7-13.4 31.3 16.1-50.0 4 5.1 1.4-12.6 21.1 6.1-45.6
52 10 7.5 3.7-13.4 31.3 16.1-50.0 6 7.7 2.9-16.0 31.6 12.6-56.6
56 4 3.0 0.8-7.5 12.5 3.5-29.0 1 1.3 0.0-6.9 5.3 0.1-26.0
58 6 4.5 1.7-9.6 18.8 7.2-36.4 7 9.0 3.7-17.6 36.8 16.3-61.6
59 3 2.3 0.5-6.5 9.4 2.0-25.0 4 5.1 1.4-12.6 21.1 6.1-45.6
73 4 3.0 0.8-7.5 12.5 3.5-29.0 1 1.3 0.0-6.9 5.3 0.1-26.0
81 3 2.3 0.5-6.5 9.4 2.0-25.0 1 1.3 0.0-6.9 5.3 0.1-26.0
82 0 0.0 0.0-2.7 0.0 0.0-10.9 1 1.3 0.0-6.9 5.3 0.1-26.0
PHR/HR-HPVs
66/68 5 3.8 1.2-8.6 15.6 5.3-32.8 1 1.3 0.0-6.9 5.3 0.1-26.0
PHR-HPVs
53 4 3.0 0.8-7.5 12.5 3.5-29.0 2 2.6 0.3-9.0 10.5 1.3-33.1
LR/PHR-HPVs
84/26 1 0.8 0.0-4.1 3.1 0.1-16.2 1 1.3 0.0-6.9 5.3 0.1-26.0
LR-HPVs
6 8 6.0 2.6-11.5 25.0 11.5-43.4 6 7.7 2.9-16.0 31.6 12.6-56.6
11 9 6.8 3.1-12.5 28.1 13.7-46.7 3 3.8 0.8-10.8 15.8 3.4-39.6
42 3 2.3 0.5-6.5 9.4 2.0-25.0 2 2.6 0.3-9.0 10.5 1.3-33.1
70 5 3.8 1.2-8.6 15.6 5.3-32.8 2 2.6 0.3-9.0 10.5 1.3-33.1
72 4 3.0 0.8-7.5 12.5 3.5-29.0 1 1.3 0.0-6.9 5.3 0.1-26.0
40/61 7 5.3 2.1-10.5 21.9 9.3-40.0 1 1.3 0.0-6.9 5.3 0.1-26.0
43/44 10 7.5 3.7-13.4 31.3 16.1-50.0 6 7.7 2.9-16.0 31.6 12.6-56.6
54/55 4 3.0 0.8-7.5 12.5 3.5-29.0 1 1.3 0.0-6.9 5.3 0.1-26.0
57/71 1 0.8 0.0-4.1 3.1 0.1-16.2 0 0.0 0.0-4.6 0.0 0.0-17.6
X 0 0 0.0-2.7 0.0 0.0-10.9 0 0.0 0.0-4.6 0.0 0.0-17.6
N: total number of times which each genotype was detected.
* Percentages referred to the total number of virus detected in each kind of lesion (133 virus in LASIL and 78 in HASIL lesions).
** Percentages referred to the number of lesions infected by one or several genotypes (32 LASIL and 19 HASIL lesions). CI95%: 95% confidence intervals used for
estimate percentages.
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to the immunodeficiency [20].
The most frequent co-infection pattern was multiple
infections with four different HPV types (25%). Although
we sought to find a dominant pattern of HPV types in
concurrent infection, we only observed random patterns.
Finally, to date, there is no established consensus re-
garding the best treatment for ASILs. The treatmentsreported for HASILs, both medical and surgical, have
not been standardized. Studies that investigated the pre-
ventive and therapeutic effects of existing HPV vaccines
have reported that vaccines can reduce persistent anal
HPV infections and HASILs among immunized MSM.
However, the use of vaccines in preventing these le-
sions in immunocompromised individuals, as expected,
has been ineffective or yielded ambiguous results [36].
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strategies. Some new strategies are under currently devel-
opment, such as the use of RNA aptamers selected
against the HPV-16 oncoprotein E7. In the future, new
strategies may play an important role in the management
of these patients [37].Conclusion
In summary, this study showed that HPV-16 was the
prevalent HPV subtype in a Spanish population. HPV-16
was associated with all grades of anal dysplasia and anal
squamous carcinomas. Also, the prevalence of high-risk
carcinogenic HPV genotypes in patients with anal path-
ology and at risk for HIV infection was remarkable.
Therefore, further studies that include a larger number
of samples, particularly samples with IC are needed to
evaluate the potential influence of these HPV genotypes
in the appearance of anal carcinomas.Study limitations
The present study had some limitations. First, the study
had a retrospective design, which relied on medical re-
cords. This study design limited the available data to the
information contained in the medical charts. The indi-
vidual’s sexual habits and race/ethnicity were not noted
in the chart. This cohort included a population of mostly
Caucasian, urban, HIV-seropositive men that were treated
in a public hospital; therefore, our findings may not be
generalize to other populations.
Second, the samples were collected from only one
hospital; thus, it may be difficult to generalize the re-
sults to the entire population of Spain. However, this
hospital was a reference centre that served patients
from many districts and municipalities of the Region
of Madrid.
Third, although more than 40 anogenital HPV types
exist, only 33 were investigated in this study. However,
these 33 included all the HPV genotypes that are typic-
ally implicated in the initiation of anal cancer.
Fourth, the modest sample size limited the statistical
power for our analyses. However, it is difficult to acquire
this kind of samples in Spain; therefore, these results
provide valuable information. In the future, it would be
of interest to obtain more samples for further studies.
Abbreviations
ASIL: Anal squamous intraepithelial lesion; HPV: Human papillomavirus; HR-
HPV: HPV type associated with a high risk of carcinogenesis; PHR-HPV: HPV
type associated with a high probability of risk of carcinogenesis; LR-HPV: HPV
type associated with a low risk of carcinogenesis; BL: Benign lesion;
LASIL: Low grade anal squamous intraepithelial lesion; HASIL: High grade
anal squamous intraepithelial lesion; IC: Invasive carcinoma.
Competing interests
The authors declare that they have non-financial competing interests.Authors’ contributions
BGE participated in the design of the study, global data acquisition, analysis
and preparation of the first draft. EMR participated in writing the first draft,
critically revised the first and final drafts, participated in the data acquisition
and participated in planning the study design. EAF conceived the design of
the study and participated in the surgical pathological data acquisition and
analysis. All authors read and approved the final manuscript.
Acknowledgments
We would like to express our gratitude to Dolores Carneros for technical
assistance and to Jesús Esteban Hernández for support in the statistical
analyses.
Author details
1Department of Histology and Anatomical Pathology, Rey Juan Carlos
University, School of Medicine, Madrid, Spain. 2Department of Anatomical
Pathology and Laboratories, Hospital General Universitario “Gregorio
Marañón”, Madrid, Spain. 3Universidad Rey Juan Carlos, Av de Atenas s/n,
E28922, Alcorcón, Madrid, Spain.
Received: 19 August 2013 Accepted: 3 December 2013
Published: 10 December 2013
References
1. Salmo E, Haboubi N: Anal Cancer: pathology, staging and evidence-based
minimum data set. Colorectal Dis 2011, 13:11–20.
2. Shia J: An update on tumors of the anal canal. Arch Pathol Lab Med 2010,
134(11):1601–1611.
3. Chiao EY, Giordano TP, Palefsky JM, Tyring S, El Serag H: Screening HIV-
infected individuals for anal cancer precursor lesions: a systematic
review. Clin Infect Dis 2006, 43(2):223–233.
4. Uronis HE, Bendell JC: Anal cancer: an overview. Oncologist 2007,
12(5):524–534.
5. Nyitray AG, da Silva RJ C, Baggio ML, Lu B, Smith D, Abrahamsen M,
Papenfuss M, Villa LL, Lazcano-Ponce E, Giuliano AR: Age-specific prevalence of
and risk factors for anal human papillomavirus (HPV) among men who have
sex with women and men who have sex with men: the HPV in men (HIM)
study. J Infect Dis 2011, 203(1):49–57.
6. Nelson RA, Levine AM, Bernstein L, Smith DD, Lai LL: Changing patterns of anal
canal carcinoma in the United States. J Clin Oncol 2013, 31(12):1569–1575.
7. Oon SF, Winter DC: Perianal condylomas, anal squamous intraepithelial
neoplasms and screening: a review of the literature. J Med Screen 2010,
17(1):44–49.
8. Tilston P: Anal human papillomavirus and anal cancer. J Clin Pathol 1997,
50(8):625–634.
9. Simard EP, Pfeiffer RM, Engels EA: Cumulative incidence of cancer among
individuals with acquired immunodeficiency syndrome in the United
States. Cancer 2011, 117(5):1089–1096.
10. Machalek DA, Poynten M, Jin F, Fairley CK, Farnsworth A, Garland SM,
Hillman RJ, Petoumenos K, Roberts J, Tabrizi SN, Templeton DJ, Grulich AE:
Anal human papillomavirus infection and associated neoplastic lesions
in men who have sex with men: a systematic review and meta-analysis.
Lancet Oncol 2012, 13(5):487–500.
11. Gormley RH, Kovarik CL: Human papillomavirus–related genital
disease in the immunocompromised host. J Am Acad Dermatol 2012,
66(6):867. e1–867.e14.
12. Darragh TM, Colgan TJ, Cox JT, Heller DS, Henry MR, Luff RD, McCalmont T,
Nayar R, Palefsky JM, Stoler MH, Wilkinson EJ, Zaino RJ, Wilbur DC, Members
of LAST Project Work Groups: The Lower Anogenital Squamous Terminology
Standardization Project for HPV-Associated Lesions: background and
consensus recommendations from the College of American Pathologists
and the American Society for Colposcopy and Cervical Pathology. Arch
Pathol Lab Med 2012, 136(10):1266–1297.
13. Santoso JT, Long M, Crigger M, Wan JY, Haefner HK: Anal intraepithelial
neoplasia in women with genital intraepithelial neoplasia. Obstet Gynecol
2010, 116(3):578–582.
14. Scholefield JH, Hickson WG, Smith JH, Rogers K, Sharp F: Anal intraepithelial
neoplasia: part of a multifocal disease process. Lancet 1992,
340(8830):1271–1273.
15. Donà MG, Palamara G, Di Carlo A, Latini A, Vocaturo A, Benevolo M,
Pimpinelli F, Giglio A, Moretto D, Impara G, Giuliani M: Prevalence,
García-Espinosa et al. Diagnostic Pathology 2013, 8:204 Page 9 of 9
http://www.diagnosticpathology.org/content/8/1/204genotype diversity and determinants of anal HPV infection in
HIV-uninfected men having sex with men. J Clin Virol 2012,
54(2):185–189.
16. Komloš KF, Kocjan BJ, Košorok P, Rus T, Toplak J, Bunič M, Poljak M:
Distribution of HPV genotypes in Slovenian patients with anal
carcinoma: preliminary results. Acta Dermatovenerol Alp Panonica Adriat
2011, 20(3):141–143.
17. Tachezy R, Smahelova J, Salakova M, Arbyn M, Rob L, Skapa P, Jirasek T,
Hamsikova E: Human papillomavirus genotype distribution in Czech
women and men with diseases etiologically linked to HPV. Plos One 2011,
6(7):e21913.
18. Kreuter A, Potthoff A, Brockmeyer NH, Gambichler T, Swoboda J, Stücker M,
Schmitt M, Pfister H, Wieland U, German Competence Network HIV/AIDS:
Anal carcinoma in human immunodeficiency virus-positive men:
results of a prospective study from Germany. Br J Dermatol 2010,
162(6):1269–1277.
19. Orlando G, Beretta R, Fasolo MM, Amendola A, Bianchi S, Mazza F, Rizzardini G,
Tanzi E: Anal HPV genotypes and related displasic lesions in Italian and
foreign born high-risk males. Vaccine 2009, 27(Suppl 1):A24–A29.
20. Abramowitz L, Jacquard AC, Jaroud F, Haesebaert J, Siproudhis L, Pradat P,
Aynaud O, Leocmach Y, Soubeyrand B, Dachez R, Riethmuller D,
Mougin C, Pretet JL, Denis F: Human papillomavirus genotype
distribution in anal cancer in France: the EDiTH V study. Int J
Cancer 2011, 129(2):433–439.
21. Glynne-Jones R, Northover JMA, Cervantes A: Anal cancer: ESMO Clinical
Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol
2010, 21(Suppl 5):v87–v92.
22. Wong AK, Chan RC, Aggarwal N, Singh MK, Nichols WS, Bose S:
Human papillomavirus genotypes in anal intraepithelial neoplasia
and anal carcinoma as detected in tissue biopsies. Mod Pathol 2010,
23(1):144–150.
23. De Villiers E-M, Fauquet C, Broker TR, Bernard H-U, zur Hausen H: Classification
of papillomaviruses. Virology 2004, 324(1):17–27.
24. De Villiers E-M: Cross-roads in the classification of papillomaviruses.
Virology 2013(13):00245–00246. doi: 10.1016/j.virol.2013.04.023.
25. Lacey HB, Wilson GE, Tilston P, Wilkins EG, Bailey AS, Corbitt G, Green PM: A
study of anal intraepithelial neoplasia in HIV positive homosexual men.
Sex Transm Infect 1999, 75(3):172–177.
26. Palefsky JM: Anal squamous intraepithelial lesions: relation to HIV and
human papillomavirus infection. J Acquir Immune Defic Syndr 1999, 21
(Suppl 1):S42–S48.
27. Hessol NA, Holly EA, Efird JT, Minkoff H, Schowalter K, Darragh TM, Burk RD,
Strickler HD, Greenblatt RM, Palefsky JM: Anal intraepithelial neoplasia in a
multisite study of HIV-infected and high-risk HIV-uninfected women. Aids
2009, 23(1):59–70.
28. Daling JR, Weiss NS, Klopfenstein LL, Cochran LE, Chow WH, Daifuku R:
Correlates of homosexual behavior and the incidence of anal cancer.
JAMA 1982, 247(14):1988–1990.
29. Peters RK, Mack TM, Bernstein L: Parallels in the epidemiology of selected
anogenital carcinomas. J Natl Cancer Inst 1984, 72(3):609–615.
30. Croxson T, Chabon AB, Rorat E, Barash IM: Intraepithelial carcinoma of the
anus in homosexual men. Dis Colon Rectum 1984, 27(5):325–330.
31. Frazer IH, Medley G, Crapper RM, Brown TC, Mackay IR, Frazer IH, Medley G,
Crapper RM, Brown TC, Mackay IR: Association between anorectal
dysplasia, human papillomavirus, and human immunodeficiency virus
infection in homosexual men. Lancet 1986, 2(8508):657–660.
32. Daling JR, Madeleine MM, Johnson LG, Schwartz SM, Shera KA, Wurscher MA,
Carter JJ, Porter PL, Galloway DA, McDougall JK: Human papillomavirus,
smoking, and sexual practices in the etiology of anal cancer. Cancer 2004,
101(2):270–280.
33. Ramamoorthy S, Liu Y-T, Luo L, Miyai K, Lu Q, Carethers JM: Detection of
multiple human papillomavirus genotypes in anal carcinoma. Infect Agent
Cancer 2010, 5:17.
34. García-Espinosa B, Moro-Rodríguez E, Alvarez-Fernández E: Genotype
distribution of human papillomavirus (HPV) in histological sections
of cervical intraepithelial neoplasia and invasive cervical carcinoma
in Madrid, Spain. BMC Cancer 2012, 12:533.
35. García-Espinosa B, Nieto-Bona MP, Rueda S, Silva-Sánchez LF, Piernas-Morales MC,
Carro-Campos P, Cortés-Lambea L, Moro-Rodríguez E: Genotype distribution
of cervical human papillomavirus DNA in women with cervical lesions in
Bioko, Equatorial Guinea. Diagn Pathol 2009, 4:31.36. Weis S: Current treatment options for management of anal intraepithelial
neoplasia. Onco Targets Ther 2013, 6:651–665.
37. Nicol C, Cesur Ö, Forrest S, Belyaeva TA, Bunka DH, Blair GE, Stonehouse NJ:
An RNA aptamer provides a novel approach for the induction of
apoptosis by targeting the HPV16 E7 oncoprotein. Plos One 2013,
8(5):e64781.
doi:10.1186/1746-1596-8-204
Cite this article as: García-Espinosa et al.: Human papillomavirus
genotypes in human immunodeficiency virus-positive patients with anal
pathology in Madrid, Spain. Diagnostic Pathology 2013 8:204.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
